• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Oscar Health (OSCR) Is Down 5.8% After Raising 2026 Guidance And Posting Record Profitability

    Simply Wall St·08/31/2026 23:16:32
    Listen to the news
    • Earlier in 2026, Oscar Health reported record first-half results and raised its full-year guidance, signaling stronger-than-previously-expected operating performance and confidence from management in the company’s trajectory.
    • This combination of upgraded guidance and record profitability has drawn fresh analyst attention, with earnings expectations being revised to reflect a potentially more resilient business model than many had assumed.
    • With Oscar Health’s raised full-year guidance now on the table, we’ll explore how this stronger outlook reshapes its investment narrative.

    Outshine the giants: these 18 early-stage AI stocks could fund your retirement.

    Oscar Health Investment Narrative Recap

    To own Oscar Health today, you need to believe its tech-enabled insurance platform can sustain profitability while controlling medical costs in a heavily regulated ACA market. The raised 2026 guidance and record first half profit strengthen the near term catalyst around earnings power, but they also heighten the key risk that any stumble in cost control or pricing could hit a stock that already embeds high expectations.

    The most relevant announcement here is Oscar’s August 2026 guidance hike, lifting expected 2026 earnings from operations to US$500 million to US$700 million from US$250 million to US$450 million. That step up reinforces the recent profitability narrative and ties directly into the catalyst of improved margins, while also putting more pressure on management to deliver against tighter analyst models and a share price now close to targets.

    Yet against these strong numbers, investors should be aware that rising medical costs and potential regulatory limits on future premium hikes could...

    Read the full narrative on Oscar Health (it's free!)

    Oscar Health's narrative projects $23.8 billion revenue and $998.5 million earnings by 2029. This requires 21.4% yearly revenue growth and about a $1.0 billion earnings increase from -$39.4 million today.

    Uncover how Oscar Health's forecasts yield a $24.20 fair value, a 19% downside to its current price.

    Exploring Other Perspectives

    OSCR 1-Year Stock Price Chart
    OSCR 1-Year Stock Price Chart

    Before this results surprise, the most cautious analysts saw slower revenue growth near 8.5% a year and only modest margin gains, so their more pessimistic view on medical cost risks and ACA exposure may shift meaningfully as the new guidance filters into updated forecasts.

    Explore 9 other fair value estimates on Oscar Health - why the stock might be a potential multi-bagger!

    Reach Your Own Conclusion

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Curious About Other Options?

    Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.